Excerpts taken from Dr. John R. Lee, M.D.'s book,
"What Your Doctor May Not Tell You about Breast Cancer." (published 2003)
"Tamoxifen is a synthetic, non-steriod drug that competes with estrogens for binding to the estrogen receptors in some parts of the body, including the breast. When estrogens bind the estrogen receptors in cells of the breast or uterus, for example, this activates cell growth and division. When tamoxifen occupies the estrogen receptor in place of the estrogen, it paralyzes the receptor, preventing it from triggering the events that result in (cancerous) cell division.... (In early studies), researchers discovered that tamoxifen did not kill cancer cells but put them into a deep sleep or quiescence. The negative side of this type of drug is that when estrogen is added back in, the cells begin to divide again.
Since 70-80% of all breast cancers contain estrogen receptors, this provided a strong impetus to test tamoxifen's anti-cancer effects in women with breast cancer and clinical trials began in the early 1970s. After the first studies, it was clear that following the first 5 years of use, the cancer-protective benefit waned. It was also clear that tamoxifen didn't work for breast cancer tumors that weren't estrogen-driven or when the cancer had spread to the lymph nodes.
Further, numerous serious side effects of the drug emerged. It has been clearly established in both animal and human studies that tamoxifen quickly causes thickening of the uterus (and that) in the first studies, a significant number of women died of uterine cancer. In response, the World Health Organization listed tamoxifen as a cancer-causing drug. (p.221-223)
*************************
Note: The WHO formerly listed tamoxifen as a cancer-causing drug. Today - Nov. 2007 - it is listed a ‘essential’ in the fight against cancer.
*************************
Continuing...
In a large study funded by the National Cancer Institute known as the Breast Cancer Prevention Trial, 13,000 women without breast cancer were given either tamoxifen or a placebo for six years or less (the average was three years.) Reportedly, 154 of the women receiving the placebo developed invasive breast cancer while only 85 women on tamoxifen did. The study had been planned to extend longer but was cut short, it's claimed, so those women on the placebo could switch to tamoxifen.
Among the women taking tamoxifen, 33 developed uterine cancer compared to only 14 in the placebo group.
Among women taking tamoxifen, 18 developed pulmonary embolism (blood clot) and 3 died compared to 6 taking placebos.
Among the women taking tamoxifen, 33 developed deep vein thrombosis (blood clot in a major vein); 22 on placebos.
Among the women taking tamoxifen, 38 women had a stroke; 24 while on the placebo.
All these side effects are well-known effects of excess estrogen. Remember, all of the above women were healthy when they entered into the trial! (p.224)
No comments:
Post a Comment